The Lattice (Official 3DHEALS Podcast)

Healthcare loves innovation right up until the bill shows up. We sit down with Dr. Nayumi Nathan (Naomi), a medical doctor turned public health and health economics leader, to unpack why medical 3D printing and additive manufacturing are often ready before the healthcare system is. If you’ve ever wondered why point-of-care 3D printing can thrive in one hospital and stall in another, the answer is usually not the printer. It is reimbursement, evidence, and policy.

We dig into how Mobility Goes Additive (MGA) builds a Europe-wide ecosystem that connects hospitals, MedTech companies, researchers, regulators, and industry partners to move from scattered pilots to real adoption. Naomi explains why the EU is uniquely complex for healthcare market access: health authority is national, so scaling custom medical devices, patient-specific implants, and hospital 3D printing programs means navigating 26+ reimbursement and governance environments. That reality changes how startups and scale-ups should plan timelines, partnerships, and investment needs.

The conversation gets concrete on what must happen next: registries, multi-center studies, and credible patient outcome data that can support evidence-based policy and sustainable payment models. We also talk advocacy, political champions, and why additive manufacturing needs “commitment followed by investment,” including scale-up funding, not just startup grants. Along the way, we reality-check bioprinting hype and share what it will take for patients to one day ask for a 3D printed knee like it’s normal.

If you care about the future of medical 3D printing in Europe and beyond, listen, subscribe, and share this with someone building in healthcare. After you listen, leave a review and tell us: what is the biggest barrier to adoption where you live?

YouTube: coming soon

Show notes: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded.

Show notes

YouTube Recording

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

We talk with Erik Boelen, founder of Qase3D, about how medical 3D printing went from a regulatory free-for-all to a world where hospital print labs function as medical device manufacturers. We break down MDR, CE marking, ISO 13485, and how to stay compliant with a lean system engineers will actually use. 
• The early “no rules” era and why proof of quality becomes unavoidable 
• How MDR and CE marking work for standard medical devices 
• Why custom-made devices can be CE-exempt yet still heavily regulated 
• ISO 13485 as a process-focused QMS and where it helps most 
• Building a lean, day-to-day QMS instead of a paperwork vault 
• The MDR Portal approach and the value of lawyer-backed interpretation 
• Practical triggers for when a growing lab should consider ISO 13485 certification  

00:00:00 - Welcome To The Regulatory Reality
00:03:10 - MDR, CE Mark, And ISO 13485
00:06:30 - Making Implants Before Clear Rules
00:08:33 - What Custom Made Really Means
00:10:20 - From Engineer To Quality Builder
00:12:12 - A Lean QMS People Actually Use
00:17:33 - The MDR Portal And Lawyer Support
00:26:45 - Scaling Compliance Without Bureaucracy
00:30:40 - The Future Of Hospital 3D Labs
00:41:05 - How To Contact Erik
00:43:15 - Disclaimer

Show notes: https://3dheals.com/episode-127-lean-compliance-for-medical-3d-printing-with-erik-boelen/

YouTube: https://youtu.be/wR7TVN4WGno?si=pvQ-Fl7VJNgNRq7F

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

The real frontier in medical 3D printing isn't the printer — it's the material. In this 3DHEALS panel, five researchers, founders, and industry leaders map the shift from printing structure to printing function, and from lab-stage novelty toward regulated, investment-grade material systems spanning soft bioresins, bioactive ceramics, and titanium lattices.

Fabian Trumper (Arrakis Bio) argues that the best biomaterials are the ones our bodies already make, and explains how his team bio-manufactures True Human Collagen at industrial scale. Prof. Kamal Choudhary (Johns Hopkins) shows why AI is reshaping materials discovery — a "ChatGPT for materials scientists" — and why so much of the field still isn't reproducible. Dr. Andrew Weems (Resilient Medical) shares how a 3D-printed scaffold could finally modernize lumpectomy surgery for breast cancer patients. Ebrahim Yarali (MERLN, Maastricht University) reveals how geometry alone — architected "meta-biomaterials" and 4D printing — can steer stem cells toward bone or cartilage. And Dr. Scott Taylor (Poly-Med) breaks down absorbable polymers that dissolve into the body once healing is done. Moderated by Craig Rosenblum, President of Himed.

In this episode:

• Human vs. synthetic biomaterials — and what cells actually "notice"
• AI-designed materials and the reproducibility crisis
• Designing devices for the surgery we already do
• 4D printing and geometry as a biological signal
• A live debate: can AI and lab models replace animal testing?

Whether you're a researcher, founder, or investor, this is a fast, opinionated tour of where medical materials are heading next.

🎥 Watch the full session and explore more 3DHEALS events: https://3dheals.com/biomaterials-frontier/

00:00:00 - Welcome And 3D Heals Missions
00:01:58 - Event Setup And Sponsor Context
00:04:08 - Absorbable Polymers And Degradation Design
00:10:07 - Pore Size And Surface Area Effects
00:12:40 - True Human Collagen For Regeneration
00:23:08 - Collagen Q&A On Regulation
00:28:58 - AI Tools For Materials Discovery
00:41:35 - AI Limits Data And Loop Closure
00:50:31 - Lumpectomy Scaffolds And Go To Market
01:01:47 - Academia Versus Startup Mindset
01:10:13 - Geometry Driven Bone Regeneration Scaffolds
01:24:11 - Acoustic Responsive And 4D Biomaterials
01:31:08 - Panel Debate On Animal Testing
01:37:39 - AI Hype Real Impact And Wish List
01:46:51 - Final Takeaways And Closing

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

A single university discovery can turn into a life-changing therapy, but only if someone can translate the science into a product, a company, and a development plan investors will actually fund. That is why we sat down with Mark from UCLA’s technology transfer and licensing team to demystify what happens after the lab result and before the biotech headline. We talk plainly about what a tech transfer office does, what it can license, and why “intellectual property” now stretches beyond patents into data, materials, and even carefully governed patient datasets.

We also zoom out to the policy foundation that made modern university commercialization possible: the Bayh-Dole Act. Mark explains how shifting IP ownership from the federal government to universities changed licensing outcomes and helped build the innovation ecosystem we now associate with US leadership in therapeutics. Along the way, we connect the dots to real UCLA impact, including major prostate cancer drugs and a licensed cure for ADA-SCID, and we unpack the tension founders often feel when a faculty inventor becomes a startup founder negotiating with their own campus.

Then we get tactical. We break down why big pharma often waits until risk is reduced, why faculty-led startups become the bridge, and how license strategy changes depending on whether you are building a therapeutic that needs exclusivity or a platform that benefits from nonexclusive access. Mark walks through diligence milestones, annual progress reporting, and the practical reality that most “shelving” is not malicious, it is a startup fighting for survival. If you care about biotech startups, university patents, and the future of the Los Angeles bioscience ecosystem, this conversation is a roadmap.

If this helped you see tech transfer differently, subscribe, share the episode with a founder or researcher, and leave a review telling us what part of the university-to-startup journey you want us to unpack next.

Show notes: coming soon

YouTube: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

Speaker bio: https://3dheals.com/new-approach-methodologies-from-theory-to-validation/

On demand video link: Coming soon

YouTube: Coming soon 

Subscribe to future events

What does it take for a biologically sophisticated model to become a tool that pharma, CROs, and regulators can actually trust?

In this 3DHEALS panel, experts in human-relevant in vitro models, 3D bioprinting, organoids, microfluidics, and drug development explore the transition from promising New Approach Methodologies (NAMs) to decision-ready assays. The discussion moves beyond the simplistic question of whether NAMs can replace animal models and instead focuses on a more practical challenge: how can these systems generate reliable evidence that improves drug-development decisions earlier?

Mike Clements examines the path from stem-cell-derived cardiac safety assays to regulatory-facing tools, including the importance of functional readouts, reproducibility, standardization, and clear context of use. Graham Craig brings a commercial perspective on why NAMs create value when they help teams advance, deprioritize, or stop programs before expensive downstream studies. Andrew Lee discusses fit-for-purpose 3D-bioprinted cardiac tissues designed to measure contractility, conduction, calcium dynamics, and arrhythmogenic behavior. Pranav Joshi explains how organoids can become assay-ready through engineering control, lifecycle quality control, standardized recovery, and transferable workflows. Alexandre Civiere shares practical skin-on-chip applications spanning permeation, wound healing, and tissue-aging models.

The panel also addresses adoption bottlenecks: model complexity versus utility, physiologic relevance, cell density, operator variability, QC gates, automation, standardization, regulatory engagement, and the role of cross-sector consortia.

Featuring:
Dr. Mike Clements, Axion BioSystems
Graham Craig, Voxell Bio
Andrew Lee, FluidForm Bio
Pranav Joshi, Bioprinting Laboratories
Alexandre Civiere, Revivo Biosystems
Moderated by Dr. Lowry Curley, Luna LifeSci

00:01:20 - 3DHEALS Mission And Networking
00:03:11 - Why Most Stem Cell Models Stall
00:05:40 - Cardiac MEA Assays And Regulators
00:10:32 - Standardization Roadmap From CIPA
00:14:33 - The Commercial Case For NAMs
00:19:20 - Fit For Purpose Beats More Complexity
00:27:08 - 3D Bioprinted Cardiac Tissues In Practice
00:35:12 - Arrhythmia Patterns And Disease Geometry
00:39:30 - Organoids To Assay Ready Workflows
00:45:57 - QC Gates Across The Organoid Lifecycle
00:50:02 - Skin Chips Permeation And Wound Healing
00:56:43 - Aging Models And Regulatory Reality
00:59:29 - Panel What Changed In Five Years
01:07:55 - Adoption Where It Moves Fast
01:13:20 - Physiological Relevance Versus Reproducibility
01:15:03 - Standardization Who Must Drive It
01:21:30 - Operator Variability And Automation Fixes
01:27:30 - Contamination And Process Traceability
01:30:12 - Why Organ Chips Still Lag
01:35:55 - AI That Helps Versus AI Theater
01:41:50 - How Much Animal Testing Can Shift
01:44:10 - Final Hopes And How To Help

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

Gravity shapes every lab workflow we take for granted, and it may be the hidden constraint behind some of the hardest problems in regenerative medicine. We sit down with Dr. Michael Roberts, a microecologist who led bioregenerative life support research at NASA’s Kennedy Space Center and now serves as Chief Scientific Officer of the International Space Station National Laboratory, to talk about what microgravity is actually good for and why biomanufacturing in space is no longer just sci-fi.

YouTube: Pending

Show notes: Pending

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

A brain organoid that can learn to play Pac-Man sounds like a stunt until you realize what it represents: measurable learning, rewiring, and human-relevant neural function that animal models often fail to predict. We talk with Dr. Lowry Curley, founder of Luna LifeSci and former CEO and co-founder of Axosim (now 28 Bio), about why neuroscience drug development breaks so often and how NAMs are finally giving teams better tools to make safer calls earlier.

If you’re building in biotech, investing in drug discovery, or just trying to understand what replaces animal testing next, this conversation gives you a clear map of the technology, the incentives, and the milestones to watch. Subscribe, share this with a colleague, and leave a review with the biggest NAM question you want answered next.

Show notes: https://3dheals.com/episode-122-new-approach-methodologies-nams-with-dr-lowry-curley/

YouTube: https://youtu.be/suVxiYZgPVE

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

Absorbable biomaterials have transformed modern medicine, enabling implants, sutures, and drug-delivery systems that safely degrade once their function is complete. Dr. Rao S. Bezwada has helped shape the field of bioresorbable polymers for more than three decades. As the inventor of Monocryl®, the absorbable suture that has generated more than $2 billion in worldwide sales, and the holder of more than 150 U.S. patents, his innovations have influenced everything from surgical sutures to next-generation biomaterials. In this episode of The Lattice, Dr. Bezwada joins Dr. Jenny Chen to discuss the science behind bioresorbable polymers, the chemistry that controls how materials degrade, and what the next generation of resorbable biomaterials could make possible.

⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional.

YouTube video: 

Show notes: https://3dheals.com/episode-121-absorbable-biomaterials-with-dr-rao-bezwada/

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D 

If you have ever wondered why dentistry can feel both high-tech and oddly hand-built at the same time, this conversation connects the dots. We talk with Dr. Nabeel Cajee, an oral implantologist in Newport Beach and faculty at Torque Academy and Implant Ninja School, about what it really takes to bring digital dentistry into daily patient care without turning your practice into a science project. From the earliest days of open-source 3D printing to today’s clinical workflows, he breaks the ecosystem down into what actually matters: data capture, dental CAD design, and fabrication with dependable post-processing.

If you care about dental 3D printing, chairside CAD/CAM, guided implant surgery, or the future of restorative dentistry, subscribe, share this with a colleague, and leave a review with your biggest question about digital workflows.

Show notes: https://3dheals.com/episode-119-where-is-dental-3d-printing-with-dr-nabeel-cajee/

YouTube Video: https://youtu.be/FOKQNpMJjb4?si=DImMXMXEiNH5oheH

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show. 

Follow us:
Twitter 
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel

About Pitch3D